german firm whose main product derived saliva vampire bat looking raise 70m euros 91m Â£49m stock market
firm paion said hoped sell 5 million shares third firm 1114 euros share
main desmoteplase based protein bats saliva
protein stops blood clotting helps bat drink victims could used help stroke sufferers
companys shares go later week scheduled start trading frankfurt stock exchange 10 february
final price top range company could valued much 200m euros
money raised spent largely developing companys drugs since desmoteplase already licensed manufacturer forest laboratories

